Seres Therapeutics Inc logo

MCRB

Seres Therapeutics Inc

$6.67

Earnings Summary

Revenue
$3.44Mn
Net Profits
$-60Mn
Net Profit Margins
-1742.22%

Highlights

Revenue:

Seres Therapeutics Inc’s revenue fell -97.28% since last year same period to $3.44Mn in the Q3 2022. On a quarterly growth basis, Seres Therapeutics Inc has generated 183.22% jump in its revenue since last 3-months.

Net Profits:

Seres Therapeutics Inc’s net profit fell -187.96% since last year same period to $-60Mn in the Q3 2022. On a quarterly growth basis, Seres Therapeutics Inc has generated 7.31% jump in its net profits since last 3-months.

Net Profit Margins:

Seres Therapeutics Inc’s net profit margin fell -3336.43% since last year same period to -1742.22% in the Q3 2022. On a quarterly growth basis, Seres Therapeutics Inc has generated 67.27% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Seres Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.45
EPS Estimate Current Year
-0.45

Highlights

EPS Estimate Current Quarter:

Seres Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a 6.79% jump from last quarter’s estimates.

EPS Estimate Current Year:

Seres Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.45.

Key Ratios

Key ratios of the Seres Therapeutics Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.7
Return on Assets (ROA)
-0.4
Return on Equity (ROE)
-1.9

Highlights

Earning Per Share (EPS):

Seres Therapeutics Inc’s earning per share (EPS) fell -32.08% since last year same period to -0.7 in the Q2 2022. This indicates that the Seres Therapeutics Inc has generated -32.08% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Seres Therapeutics Inc’s return on assets (ROA) stands at -0.4.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Seres Therapeutics Inc’s return on equity (ROE) stands at -1.9.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-0.52
-0.61
-16.46%
2022-08-03
-0.6
-0.7
-17.39%

Company Information

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease.

Organisation
Seres Therapeutics Inc
Headquarters
200 Sidney Street, Cambridge, MA, United States, 02139
Employees
333
Industry
Health Technology
CEO
Eric Shaff

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*